

Molecular Pathotyping of *Escherichia Coli* Colonising Urinary Tract and Their Drug Susceptibility Patterns Among Patients at Outpatient Department of Zonal Referral Hospital in Southern Highlands, Tanzania

Neema Pause^{a,d,*}, Livin E. Kanje^{a*}, Mandela Paul Kiwia^d, Amina Farah^a, Martin Japhet^a, Petro Paulo Nambunga^a, Sixbert Isdory Mkumbaye^{a,b,c*}

^aDepartment of Microbiology and Immunology, KCMC University, Tanzania; ^bKilimanjaro Clinical Research Institute, Tanzania; ^cClinical Laboratory, Kilimanjaro Christian Medical Centre, Tanzania; ^dMbeya Zonal Referral Hospital, Tanzania

Correspondence to Sixbert Isdory Mkumbaye (s.mkumbaye@kcri.ac.tz)

ABSTRACT

Background: Uropathogenic *E. coli* (UPEC) is the most common causative agent of both community-acquired and hospital-acquired urinary tract infections (UTIs). However, *E. coli* encompasses several other pathotypes that cause a wide range of intestinal and extraintestinal infections. For intestinal infections, the main pathotypes include Enteropathogenic *E. coli* (EPEC), Shiga toxin-producing *E. coli* (STEC), Enteroaggregative *E. coli* (EAEC), Enterotoxigenic *E. coli* (ETEC), Enteroinvasive *E. coli* (EIEC), and Diffusely Adherent *E. coli* (DAEC).

Methods: This was a cross-sectional hospital-based study conducted in the Mbeya Zonal Referral Hospital (MZRH) from December 2022 to March 2023. A total of 315 participants from whom the urine samples were collected conveniently by using a standard formula ($N = \frac{Z^2 \times P(1-P)}{e^2}$). Whereby N = minimum required sample size, Z = corresponding level of confidence (95%), P = proportion of the characteristics of interest (23%) and e = margin of error (5%). This enabled the calculation of the minimum sample size of 292 plus 10% of non-respondents.

Results: A total of 315 participants were recruited in the study; the median age (IQR) was 37 (25-53), whereby 46.7% were aged between 18 and 34 years, 30.1% were aged between 35 and 54 years, and 23.2% were older than 54 years. Male participants were 44.4%, urban participation made up 52.7% of the participants, and 60.6% of them were unemployed.

Conclusions: The findings of this study showed that the predominant pathotype associated with urinary tract infections was UPEC, followed by EAEC and EPEC, with ETEC being the least frequently identified. The study also indicated that all isolated pathotypes were resistant to ampicillin and amoxicillin/clavulanic acid.

BACKGROUND

E. coli are facultative anaerobes and gram-negative, and they can be capsulated or non-capsulated. It is normally found in the gut of both man and animals. *E. coli* poses a significant public health burden in Tanzania, particularly concerning antimicrobial resistance (AMR). Studies indicate that *E. coli* is a leading cause of urinary tract infections (UTIs), neonatal meningitis, diarrhoea and bloodstream infections, with resistance rates to commonly used antibiotics such as ampicillin, ciprofloxacin and gentamicin ranging from 28% to over 90% in various settings.¹ In Dar es Salaam, a study found that nearly a quarter of shared and private latrines were contaminated with extended-spectrum beta-lactamase (ESBL)-producing *E. coli*, highlighting the role of environmental reservoirs in transmission.² Furthermore, a study in Zanzibar reported a 13.4% prevalence of ESBL-producing

E. coli among UTI patients, with high resistance to multiple antibiotics, including amoxicillin and ceftriaxone. These findings underscore the urgent need for enhanced surveillance, improved sanitation, and judicious antibiotic use to combat the growing threat of AMR in Tanzania.³ Uropathogenic *E. coli* (UPEC) is the most common causative agent of both community-acquired and hospital-acquired urinary tract infections (UTIs). However, *E. coli* encompasses several other pathotypes that cause a wide range of intestinal and extraintestinal infections. For intestinal infections, the main pathotypes include Enteropathogenic *E. coli* (EPEC), Shiga toxin-producing *E. coli* (STEC), Enteroaggregative *E. coli* (EAEC), Enterotoxigenic *E. coli* (ETEC), Enteroinvasive *E. coli* (EIEC), and Diffusely Adherent *E. coli* (DAEC). For extraintestinal infections, the key pathotypes are neonatal meningitis-causing *E. coli*

(NMEC), sepsis-causing *E. coli* (SEPEC), and Uropathogenic *E. coli* (UPEC).⁴

Horizontal gene transfer (HGT) of resistance genes and mutations in *E. coli* enhances the likelihood of antimicrobial resistance and contributes to genetic diversity.⁵ Overlapping of genes between different pathotypes can lead to the creation of hybrid strains, enabling a single pathotype to cause infections beyond its original scope.⁶⁻⁸ As observed in a study conducted in regional referral hospitals of Tanzania, where a single *E. coli* strain was found to possess virulence genes from multiple pathotypes, creating hybrid strains.⁹

Hybrid strain formation accounts for the development of antimicrobial resistance, which is a public health concern.¹⁰ Hybrid uropathogens account for increased risk of AMR, as reported in 2019.¹¹ Antibiotic resistance not only contributes to higher morbidity and mortality rates but also leads to increased healthcare costs.¹² In low-income countries, the situation is exacerbated by limited access to healthcare, which drives patients to self-medicate, increasing the problem of drug resistance.¹³

UTI treatment is often initiated empirically, which is one of the contributing factors to antibiotic resistance and treatment failure.¹⁴ A study conducted in Uganda highlighted that improper use of antibiotics in infection treatment not only has adverse effects but also significantly increases the likelihood of microbes developing resistance.¹⁵ Furthermore, there is limited literature in most low- and middle-income countries like Tanzania regarding the specific *E. coli* pathotypes responsible for UTIs and their resistance patterns. This study aims at molecular pathotyping of *E. coli* colonising urinary tracts and their drug susceptibility patterns among patients attending the medical outpatient department at Mbeya Zonal Referral Hospital.

METHODS

Study Design, Study Participants and Study Sites

This was a cross-sectional hospital-based study conducted in the Mbeya Zonal Referral Hospital (MZRH) from December 2022 to March 2023. A total of 315 participants from whom the urine samples were collected conveniently by using a standard formula ($N = (Z^2 \times P(1-P))/e^2$). Whereby N = minimum required sample size, Z = corresponding level of confidence (95%), P = proportion of the characteristics of interest (23%) and e = margin of error (5%). This enabled the calculation of the minimum sample size of 292 plus 10% of non-respondents.

All participants aged 18 years and above who presented with signs and symptoms of UTI were recruited upon their consent. All patients under antibiotics and who were using antibiotics for the past two weeks were excluded.

Sample Collection, Culture, DST, DNA Extraction and PCR

Participants were asked to collect a clear midstream urine sample into a sterile urine container. MacConkey (MCA) powder (Oxoid, Hampshire, UK) was used for urine culture. The urine sample was inoculated onto the MCA plate, which was placed in the incubator (ThermoScientific, Massachusetts, USA) under anaerobic conditions at 37 °C for 18 to 24 hours. Colony morphology, lactose fermentation, gram staining, oxidase, triple sugar

iron, motility, and indole and citrate utilisation were among the conventional laboratory techniques used for identification and differentiation of *E. coli* from non-*E. coli*. An antibiotic susceptibility test was done by using the Kirby-Bauer disc diffusion method according to the Clinical and Laboratory Standard Institute (CLSI M-100, 2022).

DNA was Extracted through Boiling Method

10 *E. coli* colonies were transferred in 500 µl of sterile distilled water and boiled at 95°C in a water bath for 10 min. Then suspensions were centrifuged at 10000 g for 1 min, and then 200 µl of supernatants obtained from suspensions were suspended into a PCR tube. Multiplex polymerase chain reaction was used for detection of *E. coli* pathotypes. Detection of virulence factor-encoding genes associated with EPEC (*eaeA* and *bfpA*), EAEC (*aatA* and *aaiC*), EHEC (*stx1* and *stx2*), ETEC (*relt* – heat labile toxin gene and *stla* – heat stable toxin gene), UPEC (*FimH-f*) and EIEC (*ipaH*) (Table 1).

Multiplex PCR was used to detect *E. coli* pathotypes. Detection of virulence factor-encoding genes associated with EPEC (*eae*), EAEC (*aatA*), STEC (*eae*, *stx1* and *stx2*), ETEC (*elt* and *est*), and EIEC (*ipaH*). Pathotyping was performed by employing specific primers for each of the genes investigated. Each pair of primers (0.15 µl of forward and reverse primers) was used for amplifications, with 25 µl of PCR mix containing 12.5 µl of PCR master mix (Qiagen Inc., Valencia, CA, USA), 7.2 µl of nuclease-free water, and 5 µl of DNA template. The reference used strains that were *E. coli* ATCC 43887 positive for *eaeA* and *bfpA* genes of EPEC, *E. coli* ATCC 35401 positive for *relt* and *stla* genes of ETEC, and *E. coli* 43893 positive for the *ipaH* gene of EIEC. Negative control was ATCC *E. coli* 25922, which was used for standardisation of the multiplex PCR. PCR setup was: an initial denaturation step at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 10 s, annealing at 55°C for 30 s, and extension at 72°C for 10 s, followed by a final extension step at 72°C for 2 min.

Data Analysis

Data were coded, entered and analysed by using Statistical Package for Social Sciences (SPSS) version 20 (IBM SPSS Statistics V.20). Categorical variables were presented using frequencies and proportions, and numerical variables were presented using medians along with respective measures of dispersion (IQR).

Ethics Approval and Consent to Participate

This study received ethical approval from the KCMUCo Research Ethics Committee under approval number PG-175/2022. Informed consent was obtained from all participants before using their sample for research purposes.

RESULTS

Study Participants Characteristics

A total of 315 participants were recruited in the study; the median age (IQR) was 37 (25-53), whereby 46.7% were aged between 18 and 34 years, 30.1% were aged between 35 and 54 years, and 23.2% were older than 54 years. Male participants were 44.4%, urban participation made up 52.7% of the participants, and 60.6% of them were unemployed (Table 2).

TABLE 1: Primer Sequences for E. Coli Pathotyping

SN	Organism	Amplicon size (bp)	Oligonucleotide sequence (5' to 3')
1	EPEC (It)	508	5'-CACACGGAGCTCCTCAGTC-3' 5'-CCCCCAGCCTAGCTTAGTTT-3'
	EPEC		
	ETECR		
	EPEC (st)		
	ETECF		
2	EHEC (Stx1)	147	5'-GCTAAACCCAGTA ^G GGTCTTCAAAA-3' 5'-CCCGGTACA ^G GCAGGATTACAACA-3'
	EHECF		
	EHECR		
	EHEC (Stx2)		
	EHECF		
3	EHEC (Stx2)	255	5'-GGCACTGTCTGAAACTGCTCC-3' 5'-TCGCCAGTTATCTGACATTCTG-3'
	EHECF		
	EHECR		
	EPEC (eae)		
	EPECF		
4	EPEC (eae)	367	5'-TTCTTGCTGCTTGCCTGCTCTTTT-3' 5'-TTTTGTTTGTGTATCTTTGTAA-3'
	EPECF		
	EPECR		
	EIEC (ipaH)		
	EIECF		
5	EIEC (ipaH)	320	5'-CTGGTAGGTATGGTGAGG-3' 5'-CCAGGCCAACAAATTATTTCC-3'
	EIECF		
	EIECR		
	EAEC (aatA)		
	EAECF		
6	EAEC (aatA)	650	5'-CTGGCGAAAGACTGTATCAT-3' 5'-CAATGTATAGAAATCCGCTGTT-3'
	EAECF		
	EAECR		
	EAEC (aaiC)		
	EAECF		
7	EAEC (aaiC)	215	5'-ATTGTCCTCAGGCATTTCAC-3' 5'-ACGACACCCCTGATAACAA-3'
	EAECF		
	EAECR		
	EAEC (aaiC)		
	EAECF		

TABLE 2: Social Demographic Characteristics of Study Participants (N = 315)

Variable	Frequency (n)	n%	
Age			
18-34	147	46.7%	315
35-54	95	30.1%	
> 54	73	23.2%	
Median Age (IQR ^a)	37.0 (25.0, 53.0)		
Sex			
Female	175	55.6%	315
Male	140	44.4%	
Occupations			
Not Employed	191	60.6 %	315
Employed	124	39.4 %	
Residence			
Urban	166	52.7 %	315
Rural	149	47.3 %	

IQR^a – Interquartile range**Proportion *E. coli* Isolates among Study Participants**

Out of 315 participants, those between the ages of 35- 54 had the highest prevalence of *E. coli* at 38.5%, followed by those between the ages of 18- 34 with a prevalence

of 37.5%. *E. coli* was more common in females than in males, at 66.3%. Among all participants, unemployed had 63.5% proportion of *E. coli* higher than employed. Rural individuals also had 51.9% proportion of *E. coli* (Table 3).

Proportion of Isolated Bacteria

Of 315 study participants, only 138 (43.8%) had culture-positive results. Among all positive cultures eight bacterial species were isolated. Of all isolated bacteria, *E. coli* was the most common bacteria with proportion of 75.4%. And other bacteria isolated (non-*E. coli*) like *Proteus*, *Klebsiella spp* and the others accounted for 24.6% (Figure 1).

Proportion of *E. coli* Pathotypes

Out of the individuals who participated in the study, 104 cases of *E. coli* were identified. Out of these, 100 *E. coli* were successfully pathotyped, while four isolates turned out to be negative for neither of the target pathotypes. Among all the isolated *E. coli* pathotypes, the most common was UPEC (47.0%), followed by EAEC (13.0%), EPEC (13.0%), EHEC (12.0%), EIEC (10%), and finally ETEC (5.0%) (Table 4).

Drug susceptibility of the *E. coli* pathotypes

Of the 13 EAEC isolated among study participants, the majority were 92.3% resistant to both amoxicillin/clavulanic acid and ampicillin, followed by trimethoprim-sulfamethoxazole 69.2%, ciprofloxacin 53.8%, ceftriaxone 22.1%, nitrofurantoin 7.7% and meropenem 7.7%.

Of the 12 EHEC isolated, 83.3% were resistant to both amoxicillin/clavulanic acid and ampicillin, followed by trimethoprim/sulfamethoxazole 83.3%, ciprofloxacin 50.0% and ceftriaxone 33.3%. Of 10 EIEC, 100% were resistant to ampicillin, amoxicillin/clavulanic acid 90%, trimethoprim-sulfamethoxazole 80%, ceftriaxone 60.0%, ciprofloxacin 50.0%, nitrofurantoin 50% and meropenem 10%. Of the 13 EPEC, the majority were resistant to 100% ampicillin, 84.6% trimethoprim-sulfamethoxazole, 61.5% ciprofloxacin, 53.8% ceftriaxone and 30.8% nitrofurantoin. Moreover, out of 5 ETEC, 100% were resistant to amoxicillin/clavulanic acid and ampicillin, followed by 80% for ciprofloxacin, ceftriaxone and trimethoprim-sulfamethoxazole, and 20.0% for nitrofurantoin and meropenem. From 47 UPEC, 93.6% were resistant to ampicillin, 89.4% to amoxicillin/clavulanic acid, 78.7% to trimethoprim-sulfamethoxazole, 61.7% to ciprofloxacin, 51.1% to ceftriaxone, 19.1% to nitrofurantoin, and 8.5% to meropenem. EPEC and EHEC were not resistant to meropenem (Table 5).

TABLE 3: Proportion of E. Coli Isolated Among Study Participants (N=104)		
Variable	Frequency (n)	n%
Age		
18-34	39	37.5%
35-54	40	38.5%
> 54	25	24.0%
Sex		
Male	35	33.7%
Female	69	66.3%
Occupations		
Employed	38	36.5%
Not Employed	66	63.5%
Residence		
Urban	50	48.1%
Rural	54	51.9%

TABLE 4: Proportion of Pathotypes of the Isolated E. Coli (N=100)		
Pathotype	Frequency (n)	n%
UPEC	47	47.0%
EAEC	13	13.0%
EPEC	13	13.0%
EHEC	12	12.0%
EIEC	10	10.0%
ETEC	5	5.0 %
Total	100	100%




TABLE 5: Drug Resistance Profile of the Isolated E. Coli Pathotype (N = 100)						
Antibiotic	EAEC(n=13)	EHEC(n=12)	Pathotypes EIEC(n=10)	EPEC(n=13)	ETEC(n=5)	UPEC(n=47)
AMC	12 (92.3%)	10 (83.3%)	9 (90.0%)	10 (76.9%)	5 (100.0%)	42 (89.4%)
AMP	12 (92.3%)	10 (83.3%)	10 (100.0%)	13 (100.0%)	5 (100.0%)	44 (93.6%)
CRO	3 (22.1%)	4 (33.3%)	6 (60.0%)	7 (53.8%)	4 (80.0%)	24 (51.1%)
CIP	7 (53.8%)	6 (50.0%)	5 (50.0%)	8 (61.5%)	4 (80.0%)	29 (61.7%)
SXT	9 (69.2%)	10 (83.3%)	8 (80.0%)	11 (84.6%)	4 (80.0%)	37 (78.7%)
NIT	1 (7.7%)	0 (0.0%)	5 (50.0%)	4 (30.8%)	1 (20.0%)	9 (19.1%)
MEM	1 (7.7%)	0 (0.0%)	1 (10.0%)	0 (0.0%)	1 (20.0%)	4 (8.5%)

AMC: Amoxicillin/Clavulanic Acid, AMP: Ampicillin, CRO: Ceftriaxone, CIP: Ciprofloxacin, MEM: Meropenem, NIT: Nitrofurantoin, SXT: trimethoprim/sulfamethoxazole

DISCUSSION

E. coli was the leading bacterium isolated in this study with a proportion of 75.4%. Similar results were reported in Bangladesh, Northern Ethiopia and Dar es Salaam, Tanzania.¹⁰⁻¹² Also, current study results showed some similarity with the study done in Norway whereby *E. coli* was the most common isolate associated with UTI.¹⁹ These results highlight the fact that *E. coli* is the commensal of most animals and humans and is readily available in the environment. In contrast, the studies conducted in Ghana, Bosnia and Herzegovina and Cape Verde report a lower proportion of *E. coli* infections.^{9,14,15} These differences might be attributed to differences in locality, study design and sometimes ethnicity. The findings of the current study also differ from a study conducted in Kilimanjaro, which reported an *E. coli* prevalence of 46.2%.²³ The participants' ages, geographical regions and the study design may explain these disparities in findings. Different studies have used participants with different age and gender limits but also with varying sample types with different disease conditions, e.g., swab or blood samples with different disease manifestations, thus accounting for discrepancies in sample size. Ethnic differences account for different attitudes, which can be attributed to social and cultural issues and the way they practice disease prevention strategies. Other studies have deployed the more sophisticated technique such as whole genome sequencing (WGS), which gives more explanatory results.⁹ These results have varied effects on healthcare and medical research, including the necessity for specialised therapies, preventive measures, and additional research into the elements that contribute to *E. coli*'s predominance in causing UTIs.

In the current study, UPEC was found to have a 42.0% prevalence as the leading cause of UTI. Similar to a previous study that was conducted in Bangladesh.²⁴ In contrast with the study done in Germany, it was observed that the proportion of UPEC was 89.3%, which is two times higher compared to the current study.²⁵ According to the current study's findings, the proportions of EAEC, EPEC, and EIEC were 13%, 13%, and 10%, respectively. This study was consistent with earlier studies conducted in Cape Town, South Africa.²⁶ EAEC, EPEC, and ETEC proportions in this study were 13%, 13%, and 5%, respectively, which contrasted with studies conducted in Egypt and Dar es Salaam.^{19, 20} The disparities in findings are accounted for by factors like detection technology, like WGS, as well as study sites, as it has been explained elsewhere.⁹ In the current study, we discovered that ETEC and EPEC were 5% and 13% the same in the proportion of ETEC to studies conducted in India but differed in the EPEC strain.²⁹ Also, in this study we discovered that the proportion of ETEC, EHEC, EAEC and EPEC differs significantly from the study done in Iran.³⁰

In addition, the proportion of UPEC strains was 42.0% in the current study, contrary to the German study.²⁵ Also, EHEC was 13%, similar to the study conducted in Iran with a prevalence of 10%.³¹ These differences are attributed to several factors, like geographic location, sample type, age, laboratory technique used, study population and ethnicity. This implies that there is a need for medical professionals to pay special attention to cases of UTIs caused by intestinal *E. coli*, as these

infections might have distinctive characteristics, clinical presentations, or treatment responses compared to UTIs caused by UPEC.

In the current study all *E. coli* pathotypes were resistant to ampicillin, which was comparable with studies done in Haydom, Tanzania, Iran and Bosnia and Herzegovina.^{15, 24, 25} Similarly, in the current study, all *E. coli* pathotypes were more sensitive to meropenem, which was comparable to a study done in Iran.³⁰ Also, this study found that *E. coli* pathotypes isolated have a high resistance rate to ampicillin, which is in line with the previous studies conducted in South Africa.²⁶ In this study, *E. coli* pathotypes isolated were more resistant to ampicillin as well as amoxicillin/clavulanic acid, but they were more sensitive to meropenem, similar to a previous study conducted in India.³³ According to a current study, *E. coli* pathotypes isolated were more resistant to ampicillin and amoxicillin/clavulanic acid, which was similar to a study conducted in Dar es Salaam and KCMC-Moshi.^{18, 35} The present study discovered that nearly all *E. coli* pathotypes isolated were resistant to nitrofurantoin, which is similar to research done in Dar es Salaam.¹⁸

Drug susceptibility patterns among *E. coli* pathotypes were almost similar across a range of *E. coli* pathotypes. These similarities might be accounted for by the fact that all the samples were collected from people living in the same geographical location with minimal variations in terms of geographic factors like humidity and temperature. In addition, the Southern Highland regions exhibit and share the same weather conditions, which can account for a constant horizontal gene transfer among the *E. coli* strains within the environment.³⁵

Furthermore, this study observed multidrug resistance among nearly all *E. coli* pathotypes, which was consistent with previous studies in Iran, which reported numerous multidrug resistance DEC pathotypes.³⁰ Also similar to a study done in Palestine which showed MDR for isolated *E. coli*.³⁴ The findings from this study showed that ampicillin and amoxicillin/clavulanic acid exhibited levels of resistance. These results are likely to be attributed to their widespread distribution, low cost and accessibility that may encourage drug abuse and misuse. Meropenem was reported to show no resistance; this is because this drug has been used as the last resort in the study area. Its low frequency in use has demonstrated its ability to confer its effectiveness to date. This phenomenon has also been reported previously.^{3,9,11}

CONCLUSION

The findings of this study showed that the predominant pathotype associated with urinary tract infections was UPEC, followed by EAEC and EPEC, with ETEC being the least frequently identified. The study also indicated that all isolated pathotypes were resistant to ampicillin and amoxicillin/clavulanic acid. Additionally, the investigation discovered all *E. coli* pathotypes isolated were susceptible to meropenem and nitrofurantoin.

REFERENCES

1. Mshana SE, Matee M, Rweyemamu M. Antimicrobial resistance in human and animal pathogens in Zambia, Democratic Republic of Congo, Mozambique and Tanzania: an urgent need of a sustainable surveillance

- system. *Annals of clinical microbiology and antimicrobials*. 2013 Dec; 12:1-0.
2. Erb S, D'Mello-Guyett L, Malebo HM, et al. High prevalence of ESBL-Producing *E. coli* in private and shared latrines in an informal urban settlement in Dar es Salaam, Tanzania. *Antimicrobial Resistance & Infection Control*. 2018 Dec; 7:1-6.
 3. Omar MH, Kilale AM, Rashid HK, Mwakapeje ER, Onoka IM, Gimbi AA. Prevalence and risk factors for extended-spectrum β -lactamase producing antimicrobial-resistant *E. coli* in urinary tract infections among inpatients in the tertiary hospitals in Zanzibar (Tanzania): a prospective cross-sectional study. *The Pan African Medical Journal*. 2024 Apr 16;47:193.
 4. Osman KM, Mustafa AM, Elhariri M, Abdelhamed GS. Identification of serotypes and virulence markers of *Escherichia coli* isolated from human stool and urine samples in Egypt. *Indian Journal of Medical Microbiology*. 2012 Jul 1;30(3):308-13.
 5. Frazão N, Sousa A, Lässig M, Gordo I. Horizontal gene transfer overrides mutation in *Escherichia coli* colonizing the mammalian gut. *Proceedings of the National Academy of Sciences*. 2019 Sep 3;116(36):17906-15.
 6. Lermineaux NA, Cameron AD. Horizontal transfer of antibiotic resistance genes in clinical environments. *Canadian journal of microbiology*. 2019;65(1):34-44.
 7. Chib S, Ali F, Seshasayee AS. Genomewide mutational diversity in *Escherichia coli* population evolving in prolonged stationary phase. *MSphere*. 2017 Jun 28;2(3):10-128.
 8. Javadi M, Bouzari S, Oloomi M. Horizontal gene transfer and the diversity of. In: recent advances on physiology, pathogenesis and biotechnological applications 2017 Jul 12 (pp. 317-331). *IntechOpen*.
 9. Kanje LE, Kumburu H, Kuchaka D, Shayo M, Juma MA, Kimu P, Beti M, van Zwetselaar M, Wadugu B, Mmbaga BT, Mkumbaye SI. Short reads-based characterization of pathotype diversity and drug resistance among *Escherichia coli* isolated from patients attending regional referral hospitals in Tanzania. *BMC Medical Genomics*. 2024 Apr 26;17(1):110.
 10. WHO. Antimicrobial resistance. World Health Organization. 2023. Available from: <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>
 11. Li X, Fan H, Zi H, et al. Global and regional burden of bacterial antimicrobial resistance in urinary tract infections in 2019. *Journal of clinical medicine*. 2022 May 17;11(10):2817.
 12. Dadgostar P. Antimicrobial resistance: implications and costs. *Infection and drug resistance*. 2019 Dec 20:3903-10.
 13. Bryce A, Hay AD, Lane IF, Thornton HV, Wootton M, Costelloe C. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by *Escherichia coli* and association with routine use of antibiotics in primary care: systematic review and meta-analysis. *bmj*. 2016 Mar 15;352.
 14. Sharma D, Preston SE, Hage R. Emerging antibiotic resistance to bacterial isolates from human urinary tract infections in Grenada. *Cureus*. 2019 Sep 25;11(9).
 15. Hammad MA, Sulaiman SA, Aziz NA, Noor DA. Prescribing statins among patients with type 2 diabetes: The clinical gap between the guidelines and practice. *Journal of Research in Medical Sciences*. 2019 Jan 1;24(1):15.
 16. Parveen K, Momen A, Begum AA, Begum M. Prevalence of urinary tract infection during pregnancy. *Journal of Dhaka National Medical College & Hospital*. 2011;17(2):8-12.
 17. Fenta A, Dagnew M, Eshetie S, Belachew T. Bacterial profile, antibiotic susceptibility pattern and associated risk factors of urinary tract infection among clinically suspected children attending at Felege-Hiwot comprehensive and specialized hospital, Northwest Ethiopia. A prospective study. *BMC Infect Dis*. 2020; 20:1-10.
 18. Mwambete KD, Msigwa M. Prevalence of asymptomatic urinary tract infections among pregnant women residing in a rural and an urban area in Tanzania. *East and Central African Journal of Pharmaceutical Sciences*. 2017;20(1-3):27-32.
 19. van Driel AA, Notermans DW, Meima A, et al. Antibiotic resistance of *Escherichia coli* isolated from uncomplicated UTI in general practice patients over a 10-year period. *European Journal of Clinical Microbiology & Infectious Diseases*. 2019 Nov; 38:2151-8.
 20. Forson AO, Tsidi WB, Nana-Adjei D, Quarchie MN, Obeng-Nkrumah N. *Escherichia coli* bacteriuria in pregnant women in Ghana: antibiotic resistance patterns and virulence factors. *BMC research notes*. 2018 Dec; 11:1-7.
 21. Vranic SM, Uzunovic A. Antimicrobial resistance of *Escherichia coli* strains isolated from urine at outpatient population: a single laboratory experience. *Materia socio-medica*. 2016 Mar 25;28(2):121.
 22. Monteiro T, Wysocka M, Tellez E, et al. A five-year retrospective study shows increasing rates of antimicrobial drug resistance in Cabo Verde for both *Staphylococcus aureus* and *Escherichia coli*. *Journal of global antimicrobial resistance*. 2020 Sep 1; 22:483-7.
 23. Gidabayda JG, Philemon R, Abdallah MS, et al. Prevalence, aetiology, and antimicrobial susceptibility patterns of urinary tract infection amongst children admitted at Kilimanjaro Christian Medical Centre, Moshi, Tanzania. *East African Health Research Journal*. 2017 Mar 1;1(1):53-61.
 24. Rahman MM, Hossain MM, Rubaya R, et al. Association of antibiotic resistance traits in uropathogenic *Escherichia coli* (UPEC) isolates. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2022;2022(1):4251486.
 25. Toval F, Köhler CD, Vogel U, et al. Characterization of *Escherichia coli* isolates from hospital inpatients or outpatients with urinary tract infection. *Journal of clinical microbiology*. 2014 Feb;52(2):407-18.
 26. Omolajaiye SA, Afolabi KO, Iweriebor BC. Pathotyping and antibiotic resistance profiling of *Escherichia coli* isolates from children with acute diarrhoea in Amatole district municipality of Eastern Cape, South Africa. *BioMed Research International*. 2020;(1):4250165.
 27. Moyo SJ, Gro N, Matee MI, Kitundu J, Myrmel H,

- Mylvaganam H, Maselle SY, Langeland N. Age specific aetiological agents of diarrhoea in hospitalized children aged less than five years in Dar es Salaam, Tanzania. *BMC Paediatrics*. 2011 Dec; 11:1-6.
28. Khairy RM, Mohamed ES, Abdel Ghany HM, Abdelrahim SS. Phylogenic classification and virulence genes profiles of uropathogenic *E. coli* and diarrhegenic *E. coli* strains isolated from community acquired infections. *PLoS One*. 2019 Sep 12;14(9):e0222441.
 29. Sudershan RV, Kumar RN, Kulkarni B, Kashinath L, Bhaskar V, Polasa K. *E. coli* pathotypes and their antibiotic resistance in young children with diarrhea in Hyderabad, India. *Int J Curr Microbiol App Sci*. 2014 Oct 15;3(9):647-54
 30. Derakhshan S, Farhadifar F, Roshani D, Ahmadi A, Haghi F. Study on the presence of resistant diarrheagenic pathotypes in *Escherichia coli* isolated from patients with urinary tract infection. *Gastroenterology and hepatology from bed to bench*. 2019;12(4):348-57.
 31. Botelho-Nevers E, Raoult D. Host, pathogen and treatment-related prognostic factors in rickettsioses. *European journal of clinical microbiology & infectious diseases*. 2011 Oct; 30:1139-50.
 32. Fleece ME, Nshama R, Walongo T, et al. Longitudinal assessment of antibiotic resistance in fecal *Escherichia coli* in Tanzanian Children. *The American Journal of Tropical Medicine and Hygiene*. 2019 Mar 4;100(5):1110
 33. Rimoy G, Justin-Temu M, Mndolwa M. Antibiotic sensitivity of bacterial pathogens in urinary tract infections at Muhimbili National Hospital, Dar es Salaam, Tanzania. *East and Central African Journal of Pharmaceutical Sciences*. 2006;9(3):67-70.
 34. Adwan K, Jarrar N, Abu-Hijleh A, Adwan G, Awwad E. Molecular characterization of *Escherichia coli* isolates from patients with urinary tract infections in Palestine. *Journal of medical microbiology*. 2014 Feb;63(2):229-34.
 35. Fuchsman CA, Collins RE, Rocap G, Brazelton VJ. Effect of the environment on horizontal gene transfer between bacteria and archaea. *PeerJ*. 2017 Sep 29;5: e3865.

Peer Reviewed

Competing Interests: Authors declare no competing interests.

Funding: This study did not receive any funding.

Received: 22 October 2024; **Accepted:** 13 May 2025

Cite this article as Pause N, Kanje EL, Kiwia PM, Farah A, Japhet M, Nambunga PP, Mkumbaye IS. Molecular Pathotyping of *Escherichia Coli* Colonising Urinary Tract and Their Drug Susceptibility Patterns Among Patients at Outpatient Department of Zonal Referral Hospital in Southern Highlands, Tanzania. *East Afr Science J*. 2025; 7(1): 127-133. <https://doi.org/10.24248/easci.v7i1.121>

© Pause et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly cited. To view a copy of the license, visit <http://creativecommons.org/licenses/by/4.0/>. When linking to this article, please use the following permanent link: <https://doi.org/10.24248/easci.v7i1.121>
